Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

Haematologica

Volumn 92, Issue 10, 2007, Pages 1351-1358

  Kastritis, Efstathios ^a   Anagnostopoulos, Athanasios ^a   Roussou, Maria ^a   Toumanidis, Sawas ^a   Pamboukas, Constantinos ^a   Migkou, Magdalini ^a   Tassidou, Anna ^b   Xilouri, Irini ^c   Delibasi, Sossana ^b   Psimenou, Erasmia ^a   Mellou, Sofia ^d   Terpos, Evangelos ^e   Nanas, John ^a   Dimopoulos, Meletios A ^a,f  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d Henry Dynan Hospital   (Greece)

^e General Airforce Hospital   (Greece)

^f NONE   (Greece)

Author keywords

BNP; Bortezomib; Primary amyloidosis; Renal failure

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CREATININE; DEXAMETHASONE; FLUDROCORTISONE;

ADULT; AGED; AMYLOIDOSIS; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HEART AMYLOIDOSIS; HISTOLOGY; HUMAN; HYPOKALEMIA; KIDNEY AMYLOIDOSIS; MALE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PERFORMANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; RELAPSE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BORONIC ACIDS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36349024733     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11325     Document Type: Article

References (53)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.
3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.
4. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-8.
5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93:1062-6.
6. Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006;81:880-8.
7. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D. Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6.
8. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloidlight-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-70.
9. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999;24:853-5.
10. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000;25:465-70.
11. Dispenzieri A, Kyle RA, Lacy MQ, Themeau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3.
12. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
13. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004;34:149-54.
14. Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006;91:1635-43.
15. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998;101:766-9.
16. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
17. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.
18. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044-6.
19. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
20. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). ASH Annual Meeting Abstracts 2005;106:421.
21. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-51.
22. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241-6.
23. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-64.
24. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-61.
25. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM. et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-70.
26. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenaliaomide and dexamethasone in the treatment of AL amyloidosis: results of a phase II trial. Blood 2007;109:492-6.
27. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
28. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
29. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91:929-34.
30. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
31. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-505.
32. Masson S, Vago T, Baldi G, Salio M, De Angelis N, Nicolis E, et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002; 40: 761-3.
33. Dispenzieri A, Lacy MQ, Hayman SR, Kyle RA, Kumar SK, Litzow MR, et al. Powerful risk stratification in patients with AL using serum cardiac biomarkers. ASH Annual Meeting Abstracts 2005;106:1162.
34. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Cnim Acta 2001; 310:193-7.
35. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-28.
36. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
37. http://www.fda.gov/cder/foi/label/2005/021602s006lbl.pdf
38. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/α interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520-6.
39. Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P. Efficacy and safety of bortezomib in systemic AL amyloidosis - a preliminary report. ASH Annual Meeting Abstracts 2006;108:129.
40. Attaelmannan M, Levinson SS. Understanding ana identifying monoclonal gammopathies. Clin Chem 2000;46:1230-8.
41. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-8.
42. Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, et al. Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. ASH Annual Meeting Abstracts 2005;106:3496-.
43. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-7.
44. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
45. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
46. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8.
47. Leung N, Slezak JM, Bergstralh EJ, Dispenzieri A, Lacy MQ, Wolf RC, et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 2005;45:102-11.
48. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006;134:385-90.
49. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 105:1195-200.
50. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6.
51. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM. et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7.
52. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
53. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.